FDA Investigator Viviana R Ramirez
Viviana R Ramirez has conducted inspections on 8 sites in 5 countries as of 28 May 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
8
Last Inspection Date:
28 May 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
France,
United States of America,
Italy,
Spain,
Denmark
FDA Investigators that have inspected at least one site in common with Viviana R Ramirez:
Andrew Byrnes, PhD,
Anissa M Cheung,
Anna R Kwilas,
Anthony F Lorenzo,
Arsen Karapetyan,
Bharat Khurana,
Bo Liang, PhD,
Burnell M Henry,
Carla A Norris,
Caryn M Mcnab,
Christelle Mbondji Wonje,
Christopher T Peters,
Claire M Minden,
Demitria J Xiradakis,
Denise M Digiulio,
Donald C Obenhuber, PhD,
Dorothy P Kramer,
Dr. Zhihao Qiu (Peter), PhD,
Elvira R Argus,
Emmanuel Adu Gyamfi, PhD,
Erin C Hill,
Gene D Arcy,
Grace I Cortesini,
Graeme E Price,
Graeme Price,
Hector A Carrero,
Jacob L Bitterman,
Jared D Greenleaf,
Jennifer Lalama,
Kathleen M Jordan,
Kevin J Matthews,
Lauren N Barber,
Lawrence J Stringer,
LCDR Chad N Thompson,
LCDR Debra Emerson,
Lewis K Antwi,
Lily Y Koo,
Lydia I Rosas Marty,
Marie F Morin,
Megan A Haggerty,
Michael Shanks, MS,
Monica Commerford, PhD,
Nirjal Bhattarai,
Pankaj H Amin,
Patricia F Hughes, PhD,
Paul L Bellamy,
Priscilla M Pastrana,
Randa Melhem, PhD,
Raymond T Oji,
Robert J Martin,
Sean R Marcsisin,
Stephanie Mangigian, MS/OSH, RN,
Stephen D Brown,
Sukyoung Sohn,
Susan M Jackson,
Temar Q Williams,
Thai D Truong,
Thuy T Nguyen, LCDR,
Tiffany M Lucas,
Unnee Ranjan,
Viviana Matta,
Wanda E Pagan, PhD,
Zhongren Wu
Viviana R Ramirez's Documents
Publish Date | Document Type | Title |
---|---|---|
March, 2023 | FDA 483 | Catalent Maryland, Inc. - Form 483, 2023-03-10 |
May, 2023 | FDA 483 | Bristol-Myers Squibb Company - Form 483, 2023-05-05 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more